This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Breaking Up With Gilead Sciences

12/17/12 - 07:00 AM EST

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

read more >
Time For Common Sense Gun Control Has Arrived

12/17/12 - 06:30 AM EST

The tragedy in Newtown should bring gun owners and opponents together.

read more >
Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

12/10/12 - 09:00 AM EST

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

read more >
Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

12/03/12 - 07:00 AM EST

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

read more >
Nate Sadeghi's 2012 Biotech Stock Report Card

11/26/12 - 07:00 AM EST

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

read more >
Seattle Genetics: A Short Thesis That's Been Right And Wrong

11/12/12 - 07:00 AM EST

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

read more >
Arena Pharma Is Still A Good Short

11/05/12 - 07:00 AM EST

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

read more >
Achillion Pharma Worthy of New Look

10/31/12 - 08:16 AM EDT

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

read more >
United Therapeutics Could Lose The Battle For PAH Therapies

10/22/12 - 07:00 AM EDT

An FDA decision expected this week could easily go against United Therapeutics.

read more >
Page 1 of 5
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs